Insulet initiates study for closed-loop AID system for T2D

Insulet (PODD) has enrolled the first participant in a study for its fully closed-loop automated insulin delivery, AID, system for type 2 diabetes, T2D. “Our innovation strategy is grounded in empathy and steadfast in our mission to transform the lives of people with diabetes,” said Dr. Trang Ly, Senior Vice President and Chief Medical Officer at Insulet. “Enrolling the first EVOLVE study participant marks an important step toward a fully closed-loop AID system. Powered by a novel algorithm trained on extensive real and simulated patient data to safely titrate dosing and automatically adjust insulin delivery, our fully closed-loop AID system is uniquely designed to further reduce the burden for people with type 2 diabetes and their care teams.”